CA3214228A1 - Transdermal delivery of cannabidiol - Google Patents

Transdermal delivery of cannabidiol Download PDF

Info

Publication number
CA3214228A1
CA3214228A1 CA3214228A CA3214228A CA3214228A1 CA 3214228 A1 CA3214228 A1 CA 3214228A1 CA 3214228 A CA3214228 A CA 3214228A CA 3214228 A CA3214228 A CA 3214228A CA 3214228 A1 CA3214228 A1 CA 3214228A1
Authority
CA
Canada
Prior art keywords
days
once
pain
transdermal
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214228A
Other languages
English (en)
French (fr)
Inventor
Fotios M. Plakogiannis
Tamanna LATHER
Nisarg MODI
Marina BOROVINSKAYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/227,591 external-priority patent/US20210259989A1/en
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of CA3214228A1 publication Critical patent/CA3214228A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3214228A 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol Pending CA3214228A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/227,591 US20210259989A1 (en) 2019-10-14 2021-04-12 Transdermal delivery of cannabidiol
US17/227,591 2021-04-12
PCT/IB2022/053276 WO2022219468A1 (en) 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol

Publications (1)

Publication Number Publication Date
CA3214228A1 true CA3214228A1 (en) 2022-10-20

Family

ID=83640369

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214228A Pending CA3214228A1 (en) 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol

Country Status (6)

Country Link
EP (1) EP4322931A1 (de)
JP (1) JP2024513961A (de)
CN (1) CN117460503A (de)
AU (1) AU2022257344A1 (de)
CA (1) CA3214228A1 (de)
WO (1) WO2022219468A1 (de)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011514A (es) * 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
CA2760128A1 (en) * 2009-04-29 2010-11-04 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
US20110052694A1 (en) * 2009-08-31 2011-03-03 Alltranz Inc. Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
AU2018318425A1 (en) * 2017-08-14 2020-02-27 Zynerba Pharmaceuticals, Inc. Methods of treatment of osteoarthritis with transdermal cannabidiol gel
WO2019056123A1 (en) * 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
WO2021023351A1 (en) * 2019-08-05 2021-02-11 Cs Group Aps Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
MX2022004258A (es) * 2019-10-14 2022-05-26 Pike Therapeutics Inc Entrega transdermica de cannabidiol.
CN115916184A (zh) * 2020-04-20 2023-04-04 长矛治疗股份有限公司 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂
CN116075296A (zh) * 2020-07-01 2023-05-05 长矛治疗股份有限公司 用于治疗多发性硬化症的透皮药物制剂
AU2021328741A1 (en) * 2020-08-17 2023-02-02 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating Parkinson's disease
WO2022118303A1 (en) * 2020-12-03 2022-06-09 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations comprising cbd or thc for the treatment of cancer

Also Published As

Publication number Publication date
JP2024513961A (ja) 2024-03-27
AU2022257344A1 (en) 2023-10-26
EP4322931A1 (de) 2024-02-21
CN117460503A (zh) 2024-01-26
WO2022219468A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CA3155181A1 (en) Transdermal delivery of cannabidiol
CA3178878A1 (en) Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
CA2955241A1 (en) Oxymorphone transdermal patch
US20220047525A1 (en) Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
CA3155176A1 (en) Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US20220000794A1 (en) Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20210259989A1 (en) Transdermal delivery of cannabidiol
CA2578552A1 (en) Medicinal composition for percutaneous perospirone administration
CA3214228A1 (en) Transdermal delivery of cannabidiol
CA3213953A1 (en) Pharmaceutical composition and method for treating seizure disorders
US20210220325A1 (en) Transdermal delivery of dronabinol
US20210251918A1 (en) Pharmaceutical composition and method for treating seizure disorders
EP4326252A1 (de) Transdermale pharmazeutische formulierungen zur behandlung chronischer schmerzen